Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report

BACKGROUND: Nivolumab is an anti-programmed cell death protein 1 antibody, typically used as cancer immunotherapy agent. Despite multiple clinical benefits it might cause autoimmune-related side-effects, often involving the endocrine system. To our knowledge, this is the first case of nivolumab-indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Antoniou, Sofia, Bazazo, Georgios, Röckl, Ludwig, Papadakis, Marios, Berg, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454065/
https://www.ncbi.nlm.nih.gov/pubmed/34544399
http://dx.doi.org/10.1186/s12902-021-00854-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454065/
https://www.ncbi.nlm.nih.gov/pubmed/34544399
http://dx.doi.org/10.1186/s12902-021-00854-y

Ejemplares similares